US87357P1003 - Common Stock
TACTILE SYSTEMS TECHNOLOGY I
NASDAQ:TCMD (11/5/2024, 8:00:00 PM)
After market: 13.43 0 (0%)13.43
-1.68 (-11.12%)
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 992 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The firm markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The firm's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
TACTILE SYSTEMS TECHNOLOGY I
1331 Tyler St NE Ste 200
Minneapolis MINNESOTA 55416
P: 18664353948
CEO: Daniel L. Reuvers
Employees: 992
Website: https://www.tactilemedical.com/
Top movers in Tuesday's pre-market session
Authorizes Share Repurchase Program...
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology...
Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema...
Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study...
Here you can normally see the latest stock twits on TCMD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: